This novel ET‐CORM‐antibody conjugate releases carbon monoxide upon cleavage by the tumor‐associated protease cathepsin B. The construct enables selective intracellular CO delivery to HER2‐overexpressing and CatB‐expressing cells, presenting a new strategy for targeted, CO‐based cancer therapies. Here, TYRP1 is linked to neoplasm.